Biofrontera Inc. (BFRI) stock analysis
Healthcare · Drug Manufacturers - Specialty & Generic
From the 10-K filed 2026-03-19
How it makes money
Dermatology offices pay for Ameluz and RhodoLED Lamps because they use them together in photodynamic therapy.
Dermatology offices pay for Ameluz and RhodoLED Lamps because they use them together in photodynamic therapy. This light-based treatment is used to treat pre-cancerous skin lesions.
This process involves using a drug to accumulate in fast-growing cells, which is then activated by a controlled light source.
What protects it: the moat
The company relies on patent and trademark protections to maintain its market position.
Management claims that recent patent and trademark transfers strengthen its position in the United States.
However, the company faces the risk that generic versions of its primary drug could enter the market.
What growth costs
The company must fund clinical trials and research to expand its product uses.
It invests in research and development to improve its lamps and to expand the approved uses for Ameluz.
It also manages the costs of clinical trials to increase the drug's indications.
What could damage it
The emergence of generic drugs could force a significant reduction in product prices.
If generic versions of Ameluz enter the market, the company may have to lower its prices to stay competitive. This would lead to lower revenues and a loss of market share.
About Biofrontera Inc.
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.